Portal de Periódicos da CAPES

Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4 + T Cell Model without Inducing Global T Cell Activation

2011; American Society for Microbiology; Volume: 85; Issue: 12 Linguagem: Inglês

10.1128/jvi.02033-10

1098-5514

Sifei Xing, C. Korin Bullen, Neeta S. Shroff, Liang Shan, Hung‐Chih Yang, Jordyn Manucci, Shridhar Bhat, Hao Zhang, Joseph B. Margolick, Thomas C. Quinn, David M. Margolis, Janet D. Siliciano, Robert F. Siliciano,

HIV/AIDS drug development and treatment

Highly active antiretroviral therapy (HAART) can reduce plasma HIV-1 levels to below the detection limit. However, due to the latent reservoir in resting CD4(+) cells, HAART is not curative. Elimination of this reservoir is critical to curing HIV-1 infection. Agents that reactivate latent HIV-1 through nonspecific T cell activation are toxic. Here we demonstrate in a primary CD4(+) T cell model that the FDA-approved drug disulfiram reactivates latent HIV-1 without global T cell activation. The extent to which disulfiram reactivates latent HIV-1 in patient cells is unclear, but the drug alone or in combination may be useful in future eradication strategies.